Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 181

1.

Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M.

J Med Chem. 2008 Apr 24;51(8):2412-20. doi: 10.1021/jm701028q. Epub 2008 Feb 8.

PMID:
18257544
[PubMed - indexed for MEDLINE]
2.

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR.

Clin Cancer Res. 2007 Jul 1;13(13):3922-32.

PMID:
17606726
[PubMed - indexed for MEDLINE]
Free Article
3.

Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.

Tercel M, Lee AE, Hogg A, Anderson RF, Lee HH, Siim BG, Denny WA, Wilson WR.

J Med Chem. 2001 Oct 11;44(21):3511-22.

PMID:
11585455
[PubMed - indexed for MEDLINE]
4.
5.

Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs.

Wu W, Borch RF.

Mol Pharm. 2006 Jul-Aug;3(4):451-6.

PMID:
16889439
[PubMed - indexed for MEDLINE]
6.

Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.

Wilson WR, Stribbling SM, Pruijn FB, Syddall SP, Patterson AV, Liyanage HD, Smith E, Botting KJ, Tercel M.

Mol Cancer Ther. 2009 Oct;8(10):2903-13. doi: 10.1158/1535-7163.MCT-09-0571. Epub 2009 Oct 6.

PMID:
19808982
[PubMed - indexed for MEDLINE]
Free Article
7.

Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.

Lalani AS, Alters SE, Wong A, Albertella MR, Cleland JL, Henner WD.

Clin Cancer Res. 2007 Apr 1;13(7):2216-25.

PMID:
17404106
[PubMed - indexed for MEDLINE]
Free Article
8.

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV.

Radiat Res. 2007 Jun;167(6):625-36.

PMID:
17523848
[PubMed - indexed for MEDLINE]
9.

Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers.

Hay MP, Wilson WR, Moselen JW, Palmer BD, Denny WA.

J Med Chem. 1994 Feb 4;37(3):381-91.

PMID:
8308864
[PubMed - indexed for MEDLINE]
10.

Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP.

Clin Cancer Res. 2012 Feb 1;18(3):758-70. doi: 10.1158/1078-0432.CCR-11-1980. Epub 2011 Dec 19.

PMID:
22184053
[PubMed - indexed for MEDLINE]
Free Article
11.

In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.

Shibamoto Y, Tachi Y, Tanabe K, Hatta H, Nishimoto S.

Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):397-402.

PMID:
14751508
[PubMed - indexed for MEDLINE]
12.

Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.

Tercel M, Wilson WR, Anderson RF, Denny WA.

J Med Chem. 1996 Mar 1;39(5):1084-94.

PMID:
8676343
[PubMed - indexed for MEDLINE]
13.

Phosphoramidate ProTides of 2'-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties.

McGuigan C, Gilles A, Madela K, Aljarah M, Holl S, Jones S, Vernachio J, Hutchins J, Ames B, Bryant KD, Gorovits E, Ganguly B, Hunley D, Hall A, Kolykhalov A, Liu Y, Muhammad J, Raja N, Walters R, Wang J, Chamberlain S, Henson G.

J Med Chem. 2010 Jul 8;53(13):4949-57. doi: 10.1021/jm1003792.

PMID:
20527890
[PubMed - indexed for MEDLINE]
14.

DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.

Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR.

Cancer Res. 2009 May 1;69(9):3884-91. doi: 10.1158/0008-5472.CAN-08-4023. Epub 2009 Apr 14.

PMID:
19366798
[PubMed - indexed for MEDLINE]
Free Article
15.

Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin.

McGuigan C, Thiery JC, Daverio F, Jiang WG, Davies G, Mason M.

Bioorg Med Chem. 2005 May 2;13(9):3219-27.

PMID:
15809157
[PubMed - indexed for MEDLINE]
16.

Optimization of the auxiliary ligand shell of Cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs.

Ahn GO, Ware DC, Denny WA, Wilson WR.

Radiat Res. 2004 Sep;162(3):315-25.

PMID:
15333003
[PubMed - indexed for MEDLINE]
17.

Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.

Hay MP, Denny WA, Wilson WR.

Anticancer Drug Des. 1996 Jul;11(5):383-402.

PMID:
8765531
[PubMed - indexed for MEDLINE]
18.

Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.

Tercel M, Atwell GJ, Yang S, Stevenson RJ, Botting KJ, Boyd M, Smith E, Anderson RF, Denny WA, Wilson WR, Pruijn FB.

J Med Chem. 2009 Nov 26;52(22):7258-72. doi: 10.1021/jm901202b.

PMID:
19877646
[PubMed - indexed for MEDLINE]
19.

Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.

Lee HH, Wilson WR, Ferry DM, van Zijl P, Pullen SM, Denny WA.

J Med Chem. 1996 Jun 21;39(13):2508-17.

PMID:
8691448
[PubMed - indexed for MEDLINE]
20.

Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug.

Tobias SC, Borch RF.

Mol Pharm. 2004 Mar-Apr;1(2):112-6.

PMID:
15832507
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk